

Hypertriglyceridemia Market Size is expected to Grow by 2032, estimates DelveInsight

Hypertriglyceridemia Market

LAS VEGAS, NEVADA, UNITED STATES, March 26, 2024 /EINPresswire.com/ -- DelveInsight's "Hypertriglyceridemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertriglyceridemia, historical and forecasted epidemiology as well as the Hypertriglyceridemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Takeaways from the Hypertriglyceridemia Market

- As per the assessment of DelveInsight, in 2022, there were approximately 69,607,255 diagnosed prevalent cases of hypertriglyceridemia in the 7MM. These cases are expected to increase in the forecast period.
- The total diagnosed prevalent cases of severe hypertriglyceridemia in the 7MM were observed to be 3,480,363 in 2022, at a significant CAGR during the study period (2019-2032).
- Among the European countries, Germany had the highest diagnosed prevalent population of SHTG with 364,734 cases, followed by the UK with 278,983 cases in 2022. On the other hand, Spain had the lowest diagnosed prevalent population.
- The leading Hypertriglyceridemia Companies working in the market include Arrowhead Pharmaceuticals, Mochida Pharmaceutical, Ionis Pharmaceuticals, 89bio, Regeneron Pharmaceuticals, Acasti Pharma Inc., Staten Biotechnology BV, NorthSea Therapeutics B.V., Afimmune, Rivus Pharmaceuticals, Novo Nordisk, Viking Therapeutics, Liminal BioSciences, Matinas BioPharma, Arbutus Biopharma, Better Therapeutics, and others.
- Promising Hypertriglyceridemia Pipeline Therapies in the various stages of development include CaPre (TM), Lipid Lowering Medication, Ethyl Icosapentate, Volanesorsen, Omega 3 pentaenoic acid, icosapent ethyl, and others.
- March 2024: Ionis Pharmaceuticals Inc. announced a study of Phase 3 clinical trials for Olezarsen. The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
- March 2024: Arrowhead Pharmaceuticals announced a study of Phase 2 clinical trials for ARO-APOC3. The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.

Discover which therapies are expected to grab the Hypertriglyceridemia Market share @

[Hypertriglyceridemia Market Outlook](#)

Hypertriglyceridemia Overview

Hypertriglyceridemia is a medical condition characterized by high levels of triglycerides in the blood. Triglycerides are a type of fat found in the bloodstream and are a normal component of the body's metabolism, used for energy storage. However, when triglyceride levels become excessively high, it can increase the risk of cardiovascular diseases such as heart attacks and strokes. Hypertriglyceridemia can be caused by various factors including genetics, diet high in fats and sugars, obesity, diabetes, alcohol consumption, certain medications, and other medical conditions.

Hypertriglyceridemia Epidemiology Segmentation in the 7MM

- Hypertriglyceridemia Prevalent Cases
- Hypertriglyceridemia Etiology-specific Diagnosed Prevalent Cases
- Hypertriglyceridemia Diagnosed Prevalent Cases
- Hypertriglyceridemia Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Hypertriglyceridemia epidemiology trends @ [Hypertriglyceridemia Epidemiological Insights](#)

Hypertriglyceridemia Treatment Landscape

The hypertriglyceridemia treatment aims to reduce triglyceride levels and manage associated risk factors. Lifestyle modifications play a crucial role and include adopting a heart-healthy diet low in saturated fats and sugars, increasing physical activity, losing weight if necessary, and avoiding excessive alcohol consumption.

Hypertriglyceridemia Market Outlook

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hypertriglyceridemia pipeline therapies. It also thoroughly assesses the Hypertriglyceridemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics. The report gives complete detail of the market trend for each marketed Hypertriglyceridemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Hypertriglyceridemia Drugs Uptake

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hypertriglyceridemia market or expected to be launched during the study period. The analysis covers the Hypertriglyceridemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of

particular drugs. Additionally, it compares the Hypertriglyceridemia drugs based on their sale and market share.

Scope of the Hypertriglyceridemia Market Report

- Coverage- 7MM
- Study Period- 2019-2032
- Hypertriglyceridemia Companies- Arrowhead Pharmaceuticals, Mochida Pharmaceutical, Ionis Pharmaceuticals, 89bio, Regeneron Pharmaceuticals, Acasti Pharma Inc., Staten Biotechnology BV, NorthSea Therapeutics B.V., Afimmune, Rivus Pharmaceuticals, Novo Nordisk, Viking Therapeutics, Liminal BioSciences, Matinas BioPharma, Arbutus Biopharma, Better Therapeutics, and others.
- Hypertriglyceridemia Pipeline Therapies- CaPre (TM), Lipid Lowering Medication, Ethyl Icosapentate, Volanesorsen, Omega 3 pentaenoic acid, icosapent ethyl, and others.
- Hypertriglyceridemia Market Dynamics: Hypertriglyceridemia Market Drivers and Barriers

Discover more about Hypertriglyceridemia Drugs in development @ [Hypertriglyceridemia Ongoing Clinical Trials Analysis](#)

Table of Content

1. Key Insights
2. Executive Summary of Hypertriglyceridemia
3. Competitive Intelligence Analysis for Hypertriglyceridemia
4. Hypertriglyceridemia: Market Overview at a Glance
5. Hypertriglyceridemia: Disease Background and Overview
6. Patient Journey
7. Hypertriglyceridemia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Hypertriglyceridemia Unmet Needs
10. Key Endpoints of Hypertriglyceridemia Treatment
11. Hypertriglyceridemia Marketed Products
12. Hypertriglyceridemia Emerging Therapies
13. Hypertriglyceridemia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Hypertriglyceridemia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Yash Bhardwaj
DelveInsight
+91 9650213330
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/698938806>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.